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INTRODUCTION 
It is astonishing that Indians are aware of diabetes and its 
complication since 1500 BC. Charaka samhita, sushruta samhita 
and Astanga hrdaya are together called vridhatrayi or triad of 
ancients. This text deals with aetiology, symptomatology, 
pathology, prognosis, complications and principles of treatment and 
management of eight major diseases including prameha.  The 
literary meaning of Prameha is ‘Pra’ means excess, ‘Meha’ means 
urine. It has been classified into 20 types under which madhumeha 
(Diabetes Mellitus) is one of the classification, which means Madhu-
honey and meha-urine, in Charaka samhita1. 
 World wide, there is a Vast potential for Diabetes associated 
cardio-vascular disease, notably among the 33 million people in 
India (in 2003) and 23 million in China estimated to have Diabetes, 
predominantly type2. Many regions now have Diabetes prevalence 
of > 10 %.2 
 CAD is more frequent, more severe, more extensive and more 
diffuse in Diabetes as compared to Non-Diabetic. In the 
Framingham study, the incidence of IHD in Diabetes was 
approximately twice that of Non-Diabetic.3  Jacoby and Nesto4 
reported that over all prevalence of CAD was as great as 55 % 
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among adults with Diabetes as compared with 2-4 % for general 
population. In India the prevalence of Heart disease is escalating. 
 We, Indians who have highest number of Diabetic population 
in the world is at constant threat from the CAD which is more 
common in Diabetic population. Thus India faces the dangerous 
dual epidemic of Diabetes and CAD. 
 Since CAD is more common and fatal in Diabetics than in Non-
Diabetics, the treating physician should aim at primary prevention 
of IHD in Diabetics and treatment of risk factors, such as 
Dyslipidemia, obesity, Hypertension, Smoking, Insulin resistance. 
Recently we have realized in terms of Plasma Cholesterol, 
Triglycerides as well as blood pressure value should be different in 
Diabetic and Non-Diabetic subjects. In addition to the treatment of 
risk factors should be accompanied by a systemic search for silent 
disease markers such as silent myocardial ischemia which is 2-3 
times more frequent among Diabetics and thus CAD can be 
prevented before a significant clinical event. 
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AIM OF THE STUDY 
1. To study the prevalence of Silent Myocardial Ischemia in 
newly detected type 2 diabetes mellitus and also already 
known type 2 diabetic patients of various duration using 
exercise stress test. 
2. To study the impact of duration of diabetes in asymptomatic 
ischemic heart disease. 
3. To study the association and influence of other risk factors 
causing coronary artery disease in diabetics. 
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REVIEW OF LITERATURE 
HISTORY OF DIABETES IN INDIA 
 Diabetes in India has a long history since ancient time. The 
oldest reference of this disease dates back to more than 4500 
years. The name of the disease found in ‘Devik yuga’ tells it has 
been known and treated by Indians long ago. It has been 
mentioned (in Chakradatta, Rasayana chapter, Sloga 195) that Lord 
Shiva has dictated a formulation for the treatment of prameha to 
his son Lord Ganesha. Another view claims that Lord Ganesha was 
afflicted by prameha because of his eating and working habits like 
taking lots of sweets (modaka) and sitting in same place for which 
his father gave him the formulation named ‘Siva gutika’ to rectify 
the disorder.5 
EPIDEMIOLOGY OF DIABETES IN INDIA 
Burden of Diabetes: Trend And Future Projections 
 The impact of the world wide explosion of type 2 diabetes 
mellitus (which accounts for approximately 85 to 95% of all cases of 
diabetes) will remain centered in the developing countries. Since by 
the year 2025, 75% of all the people with diabetes will be in the 
developing countries as compared with 62% in 1995. By 2025, 
there will be a 42 % increase from 51-72 million in the developed 
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countries and 170% increase from 84-228 million, in the developing 
countries.6 
India already faces a grave problem with the largest number 
of subjects with diabetes (approximately 33 million in 2003) and it 
is expected to escalate further with the number increasing to 57.2 
million in the year 2025 and by the year 2030 it may be 80.9 
million.7 The prevalence estimate by the international Diabetes 
Federation (IDF) reported the worldwide prevalence to be increasing 
from 5.1-6.3% (between 2003-2025).8 
 Epidemiology studies in India on diabetes were taken up 
following several reports showing that type 2 diabetes among 
migrant Asian Indian population in several countries was high 
compared with the host population and other migrant ethnic 
groups.9 Irrespective of the differences in anthropometry, dietary 
and socioeconomic factors and migratory patterns- the migrant 
Indians showed a higher prevalence of type 2 diabetes than 
Europeans.10 
 Epidemiology study from Mauritius11 also showed the 
prevalence of type 2 DM in migrant Indian is 18%. The rate of 
prevalence of type 2 diabetes in the migrant Indian population of 
Mauritius is similar to many of the urban rates of prevalence of 
diabetes in the mainland. 
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 A series of studies from Chennai showed that the percentage 
of adult urban subjects affected had increased from 5.2% in 1984 to 
8.2% in 1989, 11.6% in 1995 and 13.9% in 2000 which further 
increased to 14.3% in 200413. A National Urban Survey in 2000 
showed that the prevalence of diabetes in urban India was 12.1% in 
subjects aged > 20 years.14 
The prevalence in all the cities was more than 9% (Varied 
from 9.3-16.6%). The prevalence in six major cities are Chennai-
13.5%, Bangalore-12.4%, Hyderabad-16.6%, Kolkata-11.7%, New 
Delhi-11.6% and Mumbai-9.3%.14 
CHORONIC COMPLICATIONS OF DIABETES 
 Long-standing diabetes mellitus is associated with an 
increased prevalence of microvascular and macrovascular diseases. 
Data from Chennai shows that the prevalence of complications of 
type 2 diabetes are as follows: Retinopathy 23.7%, nephropathy 
5.5%, peripheral neuropathy 25.5%, CHD 11.4%, PVD 4.0% and 
stroke 0.9%. Prevalence of hypertension is also high (38.2%).15 
EPIDEMILOGY OF DIABETES AND CAD – INDIAN SCENARIO 
 Indians also have three times higher risk of developing CAD 
compared to Chinese and are 20 times more likely to die due to 
CAD compared to native black or white South Africans.16  The 
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SHARE study demonstrated that south Asians had higher prevalence 
of cardiovascular disease compared to Europeans and Chinese living 
in Canada.17 
 Moreover, Indians also tend to develop CAD two to three 
decades earlier compared to Europeans.18  This predilection for CAD 
among Indians was reported fifty years ago which was confirmed 
later by several studies.19,20 
 In India approximately 2.78 million deaths are due to 
cardiovascular disease, of which over 50% is due to CAD, making 
CAD the number one killer disease in our country.21 
 Prevalence of CAD in Indians has been shown to be escalating 
in alarming proportions in the last few decades. The prevalence of 
heart disease in 1950s was 1.05%; this increased to 9.7% in 1990 
and to 11.0% in 2000 in urban population.22-25  In the Jaipur Heart 
Watch-2 study conducted in 2002, prevalence of CAD was reported 
to be 8.2%.26 
 This rising trend in CAD will shortly make India, the leader in 
CAD death rates also.27  Thus India faces the dangerous dual 
epidemic of diabetes and CAD and in many respects, the 
aetiopathogenesis of both conditions may be similar. 
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PREVALENCE OF CAD IN DIABETES 
 In CUPS study, overall, 11% of the total population had CAD 
and the age-standardized prevalence (standardized to the 1991 
census of Chennai) was 9.0%.28 
 Prevalence of CAD was higher among diabetic subjects 
(21.4%) (known diabetes 25.3% and newly diagnosed diabetes-
13.1%) compared to 14.9% among subjects with impaired glucose 
tolerance (IGT) and 9.1% among subjects with normal glucose 
tolerance.25 
 Prevalence of known myocardial infarction was three times 
higher in subjects with diabetes compared those without. At every 
age point, subjects with diabetes and impaired glucose tolerance 
had higher prevalence of CAD compared subjects with normal 
glucose tolerance. The risk for CAD thus seems to increase 
even at the stage of impaired glucose tolerance. 
MORTALITY DUE TO CAD IN DIABETIC SUBJECTS 
 Mortality among diabetic subjects with CAD is higher than in 
non-diabetic subjects.29 Studies have also shown that the 
myocardial infarction in diabetic subjects is more extensive and 
recurrence is more common in them compared to non-diabetic 
subjects. Furthermore, the prognosis after a clinical event is worse 
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in diabetic subjects compared to non-diabetic subjects. A review on 
diabetes and atheroscelerosis showed that the metabolic 
abnormalities due to diabetes predispose to vascular changes, 
which in turn lead to atherosclerotic end-points.28  Very high risk for 
CAD among diabetic subjects lead the American Diabetic Association 
to label diabetes as a cardiovascular risk equivalent.30 
 In the CUPS study the percentage of death was significantly 
higher among diabetic subjects (17/143, 11.9%) compared to non-
diabetic subjects (33/997, 3.3% p<0.001).  The American Heart 
Association has recently stated that “Diabetes is a 
cardiovascular disease.”31 
 Cardiovascular disease accounts for 70-75% of deaths in 
Diabetic people, with acute myocardial infarction being responsible 
for 30%.32 A two to four fold excess in mortality due to CAD among 
individuals with diabetes has been noted in a number of prospective 
studies encompassing a variety of ethnic and racial groups.33 
 In the study by Jackson34 et al, the prevalence of major CAD 
is increased from 9.0% in subjects with normal glucose tolerance to 
17% in those with impaired glucose tolerance and 20% in diabetes. 
Similarly the famous study of Clawson and Bell35 of approximately 
1200 diabetics and 50,000 non diabetic control shows that total 
CAD in diabetics was between 2 and 10 times greater than in 
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control. Increased severity is indicated by a greater number of 
affected vessel in an individual patient i.e higher incidence of double 
and triple vessel disease, increased extent of disease is evidenced 
by the longer individual lesions. In addition diabetics show an 
increased incidence of combined proximal and distal disease i.e 
more diffuse CAD.  Finally IHD developed at a younger age in 
diabetics as compared to non diabetics.36 
 The WHO multinational study37 on vascular disease in 
diabetics numbering 4740 and aged 35-55 years found that all 
cause mortality in diabetics was increased three fold for male and 
four fold for female diabetic patients as compared to non-diabetics. 
Among various ethnic populations, south Asians including Indian 
have a high prevalence of NIDDM and a high incidence of IHD. 
Wood et al,38 confirmed that the relative risk of AMI due to DM was 
3.3 in Asians but only 1.3 in Europeans and that clinical DM account 
for 21% of Myocardial infarction in Asians but only 3% of 
myocardial infarction in Europeans. They concluded that diabetes 
alone can account for the whole of excess deaths from IHD among 
Asians in the U.K. without the need to incorporate smoking, 
Hypertension, or Dyslipidemia. The mechanism behind the higher 
morality are unclear but contributing factors could include co-
existing diabetic cardiomyopathy, Autonomic neuropathy, the 
adverse cardiac and metabolic effects of non essential fatty acids 
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levels and increased susceptibility to ischemic damage because of a 
reduced ability to maintain high glycolytic rates during ischemia.39 
This conclusion that an underlying cardiac abnormality exists in 
diabetics, in addition to CAD, is based on the finding of a greater 
number of abnormalities of left ventricle systolic function and 
segmented wall motion and a higher incidence of recurrent 
myocardial infarction, cardiogenic shock, CCF, conduction 
disturbance and myocardial rupture.40 
SILENT MYOCARDIAL ISCHEMIA 
 Silent myocardial ischemia is defined as presence of objective 
evidence of myocardial ischemia in the absence of Angina or 
equivalent symptoms.41 
 The incidence of painless ST segment depression during 
exercise stress test in diabetic patients is more than double when 
compared to non-diabetic subjects 75% Vs 35%.42 The propensity 
of patients with diabetes to present with either silent or 
unrecognized myocardial infarction is well established.32 
 Koistinen et al,43 studied the prevalence of asymptomatic 
myocardial ischemia in diabetic subjects and found high prevalence 
of asymptomatic myocardial ischemia in diabetics 29% Vs 5% in 
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non-diabetic. Certain notable difference have been observed 
regarding the clinical features and diagnosis of IHD in diabetics.36 
1. The symptoms of Angina may be masked in diabetic patients 
leading to silent myocardial ischemia and myocardial 
infarction.  
2. Atypical anginal symptoms including symptoms of CCF are 
more common in diabetes. 
3. CAD is not well predicted by resting ECG abnormalities. 
Silent myocardial ischemia occurs more frequently in diabetic 
patients with autonomic neuropathy perhaps due to involvement of 
sensory innervations of heart.44 A heightened somatic pain 
threshold possibly due to peripheral neuropathy may also blunt the 
perception of Angina in some diabetic subjects.45 
 Rangadayalan et al,46 speculated that silent myocardial 
ischemia and decreased perception of Angina could be hazardous as 
they deprive patients warning sign thereby allowing ischemia to 
intensity further. More over studies have shown presence of 
myocardial scar in the absence of antemortem history of myocardial 
infarction which is three times more frequent in diabetic patient 
than in those without diabetes.47 
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METHODS TO DETECT SILENT MYOCARDIAL ISCHEMIA 
1. Positive Exercise test in an asymptomatic high risk individual. 
2. Transient ST segment elevation in Random (or) Ambulatory 
electrocardiography. 
3. Transient LV motion abnormality at rest or during stress in 
echocardiography. 
4. Transient perfusion defect on Thallium 201 scintigraphy. 
TREAD MILL TEST 
 Paillole et al,48 designated a study to determine the sensitivity 
and specificity of three non invasive tests viz., 48 hours Ambulatory 
ECG monitoring, Maximal ECG exercise test and intravenous 
dipyridamole Thallium Scintigraphy (DMTS). This study proved that 
as the exercise test is cheaper and more widely available than the 
DMTS, it should be used as a first line examination. DMTS may 
provide an alternative solution for those patient who can not 
perform maximal exercise or those with a typical clinical 
presentation. Now TMT is most frequently used to estimate 
prognosis and to determine the likelihood and extent of CAD, the 
patients functional capacity and the effect of therapy.  A number of 
studies has shown that, in TMT positive patients, 76% of patients 
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have coronary stenosis of 50% or greater on Angiography and are 
true positive. The rest 24% are labeled as false positive. In TMT 
negative patients angiography showed 38% are false negative. 
Females have high false positive 54% Vs male 17%.49 
 The predictive value of positive test may be further enhanced 
by considering of not only ST segment response but also exercise 
time, workload, BP response, Heart rate response.50 
 The treadmill protocol should be consistent, with the patient’s 
physical capacity and the purpose of the test.  In healthy individuals 
the standard “Bruce” protocol is popular and large diagnostic and 
prognostic data base has been published using this protocol.51 
 The Bruce multistage maximal treadmill protocol has 3 minute 
periods to allow achievement of a steady state before workload is 
increased. In older individuals (or) those whose exercise capacity is 
limited by cardiac disease, the protocol can be modified by two 3 
minutes warming up stages at 1.7 miles per hour and with 0 
percent grade and 1.7 miles per hour and 5% grade. 
PRINCIPLES OF EXECISE ELECTRO CARDIOGRAPHY 
 The principle of exercise testing is the measurement of 
capacity of the coronary circulation to augment coronary blood flow 
in response to increase oxygen demand because the heart rate at 
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resting work load extract almost all of the available oxygen 75 to 
80%, increased cardiac work require an increase in blood flow which 
is commensurable with the work. An increase in the cardiac output 
is accomplished in large part by a increase in heart rate. There is a 
linear relationship and one can reliably be estimated from the other. 
Therefore when a subject increases his heart rate from the basal 
state to an age related maximum, we can predict that his heart has 
reached its maximum cardiac output and has increased coronary 
blood flow as much as possible. When the coronary circulation is 
unable to augment during exercise such as in CAD, It manifests as 
familiar ST segment depression in the ECG. 
EXERCISE PHYSIOLOGY DURING TREADMILL TEST 
 Cardiac output increases 4-6 folds above basal levels during 
strenuous exertion in the upright position, depending on genetic 
environment and level of training. The maximum heart rate (MHR) 
can be estimated from the formula.51 
 MHR = 220 – age in years (with standard deviation of 12 
beats/min). 
The age predicted maximum heart rate is useful measurement 
for safety reasons. 
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 In post exercise phase, hemodynamics returns to baseline 
within minutes of termination of exercise. Vagal reactivation is an 
important cardiac deceleration mechanism after exercise and the 
acceleration is well in trained athletes but blunted in patients with 
chronic heart failure.51 
 The work done during the treadmill test is expressed in 
metabolic equivalents (MET) which refer to unit of oxygen uptake in 
a sitting, resting person. One MET is equivalent to 3.5 ml O2/kg/min 
of body weight.51 
MET’s ASSOCIATES WITH ACTIVITY 
 Work activities can be calculated in multiples of METS. The 
measurements obtained with cardiopulmonary exercise testing are 
useful in understanding an individual patient response to exercise 
and can be useful in the diagnosis and evaluation of a patient with 
dyspnoea.51 
TYPES OF ST SEGMENT DISPLACEMENT IN TREADMILL 
 In normal persons the PR, QRS and QT intervals shorten as 
heart rate increases – ‘P’ amplitude increases and the PR segment 
becomes progressively more down sloping in the inferior leads. 
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 ‘J’ (Junctional) point depression is a normal finding during 
exercise. In patients with myocardial ischemia, however the ST 
segment usually becomes more horizontal as the severity of the 
ischemic response worsens. With progressive exercise the depth of 
the ST segment depression may increase, involving more ECG leads 
and the patient may develop angina.51 
 In the immediate post recovery part the ST segment 
displacement may persist with down slopping ST segment and ‘T’ 
wave inversion, gradually returning to baseline after 5-10 minutes. 
In about 10% of patients the ischemic response may appear only in 
the recovery phase. 
The eight different ECG patterns seen during exercise testing: 
1. The normal and rapid upsloping ST segment response are 
normal response to exercise. 
2. J Point depression with rapid upsloping ST segments is a 
common response in an older, apparently healthy population. 
3. Minor ST depression can occur occasionally at sub maximal 
workloads in patients with CAD in this illustration, the ST 
segment is depressed 0.09 mV (0.9 mm) 80 m sec after the J 
point. 
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4. The slow upsloping ST segment pattern often demonstrates 
an ischemic response in patients with known coronary disease 
or those with a high pretest clinical risk of coronary disease. 
Criteria for slow upsloping ST segment depression include J 
point and ST 80 depression of 0.15 mV or more and ST 
segment slope of more than 1.0 mV/sec. 
5. Classic criteria for myocardial ischemia include horizontal ST 
segment depression observed when both the J point and ST 
80 depression are 0.1 mV or more and ST segment slope is 
within the range of 0.1 mV/sec. 
6. Down sloping ST segment depression occurs when the J point 
and ST 80 depression are 0.1 mV and ST segment slope is -
1.0 mV/sec. 
7. ST segment elevation in a non Q wave non infarct lead occurs 
when the J point and ST 60 are 1.0 mV or greater and 
represents a severe ischemic response. 
8. ST segment elevation in an infract territory (Q wave lead) 
indicates a severe wall motion abnormality and in most cases 
is not considered as ischemic response. 
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TYPES OF ST SEGMENT DISPLACEMENT IN TREADMILL 
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NON CORONARY CAUSES OF ST SEGMENT DEPRESSION51 
1. Severe aortic stenosis 9. Glucose Load 
2. Severe hypertension 10. Left ventricular hypertrophy 
3. Cardiomyopathy 11. Hyperventilation 
4. Anemia  12. Mitral valve prolapse 
5. Hypokalemia 
13.Intraventricular conduction   
     disturbance 
6. Severe hypoxia 14. Preexcitation syndrome 
7. Digitalis use 
15. Severe volume overload (aortic, 
      mitral regurgitation) 
8. Sudden excessive 
    exercise 
16. Supraventricular tachyarrhythmias 
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Exercise Parameters Associated with an Adverse Prognosis 
and Multivessel Coronary Artery Disease51 
1. Duration of Symptom-limiting exercise <5 METs 
2. Failure to increase systolic blood pressure ≥ 120mm Hg, or a     
    sustained decrease ≥ 10mm Hg, or below rest levels, during    
    progressive exercise. 
3. ST segment depression ≥ 2mm, down sloping ST segment,    
    starting at < 5 METs, involving ≥ 5 min into recovery. 
4. Exercise-induced ST segment elevation (a VR excluded) 
5. Angina pectoris at low exercise workloads 
6. Reproducible sustained (> 30 sec) or symptomatic ventricular  
    tachycardia 
7. Acute systemic illness (pulmonary embolism, aortic dissection) 
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MEASUREMENT OF ST SEGMENT DISPLACEMENT 
 For purpose of interpretation, the PQ junction is usually 
chosen as the iso electric point. The TP segment represents a true 
iso electric point but is an impractical choice for most routine clinical 
measurements. The development of 0.1 mV (or) greater of ‘J’ point 
depression measurement from the PQ junction with a relatively flat 
ST segment slope (e.g. < 0.7 to 1 MV /sec), depressed 0.10 MV (or) 
more 80 m.sec after the ‘J’ point (ST 80) in three consecutive beats 
with a stable baseline is considered to be an abnormal response.51 
 When the ST 80 measurement is difficult to determine at 
rapid heart rate (> 130 beats/min) the ST 60 measurement should 
be used. The ST segment at rest may occasionally be depressed. 
When this occurring the ‘J’ point and ST 60 (or) ST 80 measurement 
should be depressed an additional 0.1 MV (or) greater to be 
considered abnormal.51 
 When the degree of resting ST depression is 0.1 MV (or) 
greater, the exercise ECG becomes less specific and myocardial 
imaging modalities should be considered. Exercise induced ST 
segment depression does not localize the site of myocardial 
ischemia nor does it provide a clue about which coronary artery 
involved. But exercise induced ST segment elevation is relatively 
specific for the territory of myocardial ischemia and coronary artery 
involved.51 
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MECHANISM OF ST SEGMENT DEPRESSION 
 Dynamic changes in coronary artery at the site of an 
atherosclerotic plaque may result in diminished coronary flow during 
static (or) dynamic exercise, instead of the expected that normally 
occur from coronary vasodilatation in a normal vessel; that is 
perfusion present distal to the stenotic plaque actually falls during 
exercise, resulting in reduced subendocardial blood flow. Thus 
regional left ventricular myocardial ischemia may result not only 
from an increase in myocardial oxygen demand during exercise but 
also from a limitation of coronary flow as a result of coronary 
vasoconstriction (or) inability of vessels to sufficiently vasodilate at 
(or) near the site of an atherosclerotic plaque.51 
In normal persons, the action potential duration of the 
endocardial region is longer than that of the epicardial region and 
ventricular repolarisation is from epicardium to endocardium. The 
action potential duration is shortened in the presence of myocardial 
ischemia and electrical gradients are created, resulting in ST 
segment depression (or) elevation depending on the surface ECG 
leads. At the molecular levels, activation of sarcolemmal ATP – 
sensitive potassium channels by ischemia ATP depletion may play a 
role.  
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NON ELECTRO CARDIOGRAPHIC OBSERVATIONS IN TREAD 
MILL 
EXERCISE CAPACITY 
 There appears to be no correlation between performance of 
maximal testing and predictive value of ST segment response. 
However the development of evidence of ischemia at low work load 
is associated relatively high risk of subsequent events.52 
EXERCISE TIME 
 The importance of exercise time is evident.  ST depression 
occurring after 6 minutes of standard Bruce protocol is associated 
with relative risk of 6.7, 3.6 in men and women respectively when 
compared to ST depression occurring within 5 minutes associated 
with relative risk of 14.7, 5.6 in men and women respectively.53 
BLOOD PRESSURE 
 Perhaps the most important parameter to be monitored 
closely is blood pressure for patient safety and also for its diagnostic 
contribution. The normal exercise response is to increase systolic BP 
progressively with increasing work loads to a peak response ranging 
from 160-200 mmHg with the higher range of the scale in older 
patients with less compliant vascular system. In asymptomatic 
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normotensive individuals an exaggerated exercise systolic BP to 214 
mmHg (or) greater (or) an elevated systolic (or) diastolic BP at the 
3rd minute of recovery is associated with significant increased long 
term risk of hypertension.51 
 If blood pressure fails to increase with increasing work load 
(or) drops at less than maximal work load, this can be a strong 
predictor of CAD.51 
HEART RATE RESPONSE 
 The magnitude of heart rate response is related to cardiac 
reserve, the state of physical fitness and is dependant on interplay 
between sympathetic and parasympathetic nervous system. Blunted 
heart rate response to Exercise termed as chronotrophic 
incompetence increases the risk of future coronary event in 
Diabetes.54 
  As stated by Borlow irrespective of age, gender and risk 
factors, exercise stress testing remains a most practicable and 
cost effective method for detecting CAD. This should not be 
judged unreliable because of high prevalence of false positive 
results.55 
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ATHEROTHROMBOTIC DISEASE 
 Several risk factors have been identified for CAD in General 
population.  RISK FACTORS ARE. 
I PREDISPOSING FACTORS 
 1. Age 
 2. Sex 
 3. Family History 
 4. Genes 
II RISK MODIFYING BEHAVIOURS 
1. Smoking  
2. Athero genic diet  
3. High Alchocol consumption  
4. Physical activity 
III METABOLIC RISK FACTORS 
1. Dyslipidemia  
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2. Hypertension 
3. Obesity  
4. Diabetes mellitus 
5. Metabolic Syndrome 
IV DISEASE MARKERS 
1. Calcium Score  
2. Catheterization result  
3. Stress test results  
4. Left Ventricular Hypertrophy  
5. Previous History of Myocardial  Infarction  
6. Inflammatory State 
SMOKING 
 The effect of smoking by a diabetic is to double or Triple the 
already increased risk of IHD and also increase CAD mortality by 
50%. Chronic cigarette smokers are insulin resistant, hyper 
insulinemic and dyslipidemic 51 
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FAMILY HISTORY OF DIABETES AND IHD 
 Strong Familial aggregation of the disease has been noted in 
Indians and also in other Asian populations. In India nearly 75% of 
the Type 2 Diabetic patients have first degree family history of 
Diabetes. The risk of the offspring developing diabetes with a 
parental history increases above 50% and it is around 40% if the 
proband has the diabetic sibling.56,57  Family history of IHD is an 
important independent risk factor for CAD in General population. 
PHYSICAL INACTIVITY AND SEDENTARY OCCUPATION 
 The impact of physical inactivity is manifested more markedly 
in populations which had been accustomed to habitual heavy 
physical activity. Migration from rural areas to urban slums in 
metropolitan cities leads to obesity, glucose intolerance and 
dyslipidemia.58,59  The risk of developing diabetes and CAD was 
more in subjects who followed a sedentary lifestyle.60 
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METABOLIC SYNDROME 
 Clustering of multiple cardiovascular risk factors has been 
known for at least 80 years. Kylin initially reported that 
hypertension, hyperglycemia and high uric acid levels in the same 
individual predicted increased risk of coronary heart disease.61 
Insulin resistance in diabetes was reported by Himsworth in 1939 in 
a series of Goulstonian Lectures to the Royal College of Physicians 
in London. He challenged the conventional wisdom that all diabetes 
was caused by lack of insulin and demonstrated that “a state of 
diabetes may result form inefficient action of insulin as well as 
deficiency of insulin”62 
Insulin resistance syndrome as a single disease entity was 
reported in 1988 by Reaven who reported clustering of multiple 
abnormalities of glucose and lipid metabolism and called it 
syndrome X or insulin resistance syndrome.63  He included insulin 
resistance, hyperglycemia, hypertension, low HDL cholesterol and 
high VLDL triglycerides. He surprisingly missed obesity or visceral 
obesity from the definition which was later added as a crucial 
abnormality. Various names were subsequently proposed the latest 
being the metabolic syndrome.61  The cause of the metabolic 
syndrome remains obscure. Reaven proposed that insulin 
resistance was the most important abonormality.64 
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METABOLIC  SYNDROME - A PREDICTOR OF 
CARDIOVASCULAR DISEASE 
 The relation of insulin resistance to cardiovascular risk, 
particularly to coronary artery disease (CAD) has been well 
established in many prospective studies in the West. In 1,209 Finish 
men aged 42-60 years, the 10-year CVD risk was increased 2.1-and 
2.5-fold with the ATPIII and WHO metabolic syndrome definition, 
respectively.64 The metabolic syndrome alone predicted ~ 25% of 
all new-onset CVD mortality by 1.2-2.8 times.65  
PREVALANCE OF METABOLIC SYNDROME IN INDIA  
 A recent population based study in south Indians compared 
prevalence of metabolic syndrome using WHO, ATP III and IDF 
definitions, the prevalence of metabolic syndrome were 23.2% 
18.3% and 25.8% respectively.52 
PATHOGENESIS OF ATHEROSLEROSIS IN DIABETICS 
ROLE OF HYPERGLYCEMIA 
 Cardiovascular risk rises as blood glucose increases above 
subdiabetic levels. The relationship may be J-shaped. In diabetic 
people, tight glycemic control has not yet been shown to reduce 
macrovascular events, except of metformin treatment, which 
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significantly decreased fatal myocardial infarction rate in type 2 
diabetic patients. Other actions of metformin (reducing pressure 
and obesity) may be responsible.66 
 Hyperglycemia leads to advanced glycation end-products 
(AGE) formation in the arterial wall, damaging structural proteins 
and generating toxic reactive oxygen species. Sequelae include 
increased endothelial permeability, impaired nitrous oxide (NO) 
mediated vasorelaxation, upregulation of procoagulant and 
adhesion proteins on the endothelium and attraction of 
macrophages that form foam cells. AGEs interact with specific 
receptors (RAGEs) on endothelial and other cells to cause specific 
effects. Genetic polymorphisms of the RAGE gene may modulate 
production of inflammatory mediators in arteries. Insulin stimulates 
vascular smooth muscle cell proliferation and production of the 
fibrinolysis inhibitor, plasminogen activator inhibitor (PAI). High 
insulin levels in insulin resistant states may therefore be 
atherogenic. Other commonly associated risk factors are 
hypertension (30-40% of diabetic people), dyslipidemia - typically 
normal low dentsity lipoproteins, dominated by highly atherogenic 
small dense low-density lipoprotein, low high-density lipoproteins, 
raised triglycerides and obesity, an independent risk factor.66 
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DYSLIPIDEMIA IN TYPE 2 DIABETES MELLITUS 
 Lipid metabolism is commonly disarranged by diabetes 
mellitus, often with additional contributions from coexistent renal or 
hepatic disorders. These lipid alterations play an important role in 
the development of atherosclerosis and contribute to the instability 
of atheromatous plaques. Gross hypercholesterolemia but at any 
given level of cholesterol, a diabetic subject has two to three times 
the cardiovascular risk of non-diabetic.66 
 Lipid abnormalities associated with type 1 diabetes are largely 
related to the level of glycemic control. Hyperglycemia is associated 
with raised low-density lipoprotein (LDL) cholesterol and triglyceride 
concentrations and low HDL-cholesterol abnormalities which are 
reversed by normalizing glycemia.66 
 The pattern of dyslipidemia in type 2 diabetes is that 
characteristically seen in the insulin-resistant states and the 
metabolic syndrome. Low HDL and raised triglyceride concentrations 
are accompanied by normal LDL-cholesterol levels, although this is 
likely to be dominated by highly atherogenic small dense LDL 
particles. Non-diabetic but insulin resistant first degree relatives of 
type 2 diabetic subjects share this atherogenic profile, suggesting 
that it precedes the development of clinical diabetes.66 
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SYSTEMIC HYPERTENSION 
 Hypertension commonly coexists with type 1 and type 2 
diabetes and is particularly associated with diabetic nephropathy. In 
its own right, it is a major risk factor for both myocardial infarction 
and stroke. In the UKPDS, 32% of type 2 diabetic males and 45% 
of females with no clinical evidence of atheromatous disease were 
hypertensive (according to the World Health Organization criteria of 
systolic pressure> 160 mmHg and / or diastolic > 90 mm Hg) or 
were taking antihypertensive drugs. In male subjects who already 
had coronary artery disease, the prevalence of hypertension was 
even higher at 46%.66 
 Hypertension is an important feature of the cluster of 
cardiovascular risk factors termed the metabolic syndrome. The 
links between these factors remain largely unexplained. The 
characteristic dyslipidemia of insulin resistance may contribute to 
hypertension, as small dense LDL particles are especially 
susceptible to oxidation and oxidized LDL can suppress endothelial 
NO production and so promote vascoconstriction; 
hypertriglyceridemia also impairs endothelium dependent 
vasorelaxation. A role of dyslipidemia is supported by studies 
showing that fibrates used to treat hypercholesteroleamia also 
reduced the prevalence of hypertension by up to 25%.66 
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OBESITY 
 Obesity predisposes to type 2 diabetes, hypertension, 
dyslipidaemia and ultimately atheroma – one of the major causes of 
premature death in the obese. Indeed, obesity is now recognized as 
a cardiovascular risk factor in its own right.66 
 Truncal or male-pattern obesity, with excess fat deposited 
both subcutaneously around the abdomen and within the visceral 
cavity is particularly associated with type 2 diabetes and the other 
components of the metabolic syndrome. For unknown reasons, 
truncal obesity is associated with insulin resistance and 
proinflammatory responses that cause glucose intolerance and a 
highly atherogenic risk profile. Candidate mediators produced by 
adipose tissue that may contribute include NEFAs and cytokines 
such as TNF-alpha. Reduced levels of adiponectin, an insulin 
sensitizing protein whose secretion by adipose tissue is 
paradoxically decreased in obesity, may also contribute to both 
insulin resistance and atherogenesis. The thiazolidinediones 
ameliorate some of these adverse effects of adipose tissue (e.g. 
lowering NEFA levels), raising the prospect that these agents may 
reduce cardiovascular risk in Type 2 Diabetes.66 
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HAEMOSTASIS IN DIABETES 
 Diabetes is associated with a variety of abnormalities in 
coagulation, fibrinolysis and platelet function. These include 
increase in specific procoagulant proteins – factor VIII, vWF, factor 
VII, factor X and fibrinogen together with decrease in coagulation 
inhibitor proteins and antithrombin III.  Some of these disturbances 
differ quantitatively between type 1 and type 2 diabetes and some 
show particularly strong associations with atherothrombotic disease 
and with microvascular complications, especially nephropathy.66 
ATHERO THROMBOTIC DISEASE 
 Atheroma develops earlier and faster in diabetes, leading to 
widespread lesions throughout the arterial tree, including the 
smaller arteries. Thickening of the intima is an early change. 
Hyaline degeneration and thickening of the muscular media may 
contribute to hypertension and often undergoes calcification (medial 
sclerosis). An important functional abnormality is impaired arterial 
relaxation, due to failure of the endothelium to produce nitrous 
oxide (NO), a potent vasodilator. Procoagulant changes on the 
endothelial surface promote adhesion of macrophages (the 
precursors of foam cells of the atheromatous plaque) and platelets, 
favoring thrombosis. Platelet rich thrombus in the coronary arteries 
is unstable and likely to rupture, causing acute coronary occlusion.66 
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CLINICAL SYNDROMES AND MANAGEMENT 
 Myocardial ischemia may present atypically or without pain 
and ‘silent’ ischemia carries a worse prognosis than in non-diabetic 
people. Typical symptoms such as dyspnoea, fatigue, or nausea and 
vomiting were the presenting complaint in DM with MI in 32-42% 
compared with 6-15% in non DM with MI.32  Vascular disease in the 
legs and cerebral circulation commonly coexist and are two to three 
times more frequent than in the general population. Early and 
extensive investigation (including invasive test such as coronary 
angiography) may therefore be needed in patients with few 
symptoms.66 
 Primary preventative measures includes weight loss if obese, 
regular physical activity and smoking cessation; optimizing glycemic 
control, using metformin in obese type 2 patients; correcting 
dyslipidemia and hypertension; and aspirin (75 mg / day). Target 
cholesterol concentration is <4.8 mmol/L and blood pressure should 
be <135/85 mmHg.66 
 Beta blockers and angiotensin-converting enzyme (ACE) 
inhibitors are useful in treating angina and hypertension and also 
have cardioprotective effects in diabetic patients. ACE inhibitors also 
slow the progression of nephropathy and some calcium channel 
antagonists decrease the risk of infarction in diabetic people. Heart 
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failure is treated conventionally with ACE inhibitors and diuretics; 
certain beta blockers (e.g. carvedilol) may also be useful.66 
 Unstable angina carries a 50% higher risk of progression to 
myocardial infarction than in non-diabetic subjects and requires 
intensive treatment with low molecular-weight heparin and a beta 
blocker; addition of either clopidogrel or a platelet glycoprotein 
inhibitor further reduces risk of infarction or death. Urgent coronary 
revascularization is indicated if medical measures fail.66 
 Acute myocardial infarction should be treated with immediate 
thrombolysis (even in the presence of retinopathy), aspirin and a 
cardioselective beta-blocker. An ACE inhibitor should be given early 
unless contraindicated. Blood glucose should be tightly controlled in 
all diabetic patients, according to the Diabetes Mellitus Insulin 
Glucose Infusion in Acute Myocardial Infarction (DIGAMI) protocol, 
insulin / glucose solution infused intravenously to maintain levels of 
7-11 mmol/L for at least 24 hours, followed by intensive 
subcutaneous insulin treatment for at least 3 months. Insulin given 
in this way may reduce myocardium from non-esterified fatty acids 
and block excessive neuroendocrine activation.66 
 Coronary revascularization relieves symptoms as effectively in 
diabetic as in non-diabetic people, although long-term survival is 
lower. Percutaneous transluminal coronary angioplasty (PTCA) with 
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stenting (and probably a platelet inhibitor) is preferred for 
accessible lesions in larger vessels. Coronary artery bypass grafting 
(CABG) is generally reserved for difficult or multiple occlusions and 
for re-stenosis after angioplasty.66 
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MATERIALS AND METHODS 
PLACE OF STUDY: 
Government Kilpauk Medical College Hospital, Chennai-10. 
DURATION OF STUDY: July 2006 to June 2007 
INCLUSION CRITERIA: 
1. Newly detected Type 2 DM – Patients detected Type-2 
diabetes recently within 6 months duration. 
Patients diagnosed to have DM on full filling any one of    
the following criteria devised by ADA Recommendation. 
1. Fasting plasma glucose ≥ 126mg% 
2. Post prandial plasma glucose ≥ 200 mg% 
3. Symptoms of diabetes with Random plasma 
glucose ≥ 200 mg %. 
2. Known Type 2 Diabetic patients of various duration on           
treatment. 
3. Age between 30 and 60 years. 
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4. Patients should not have any CAD symptoms. 
5. Resting ECG, X-ray chest and Echocardiography should 
be normal. 
EXCLUSION CRITERIA 
1. Type 1 Diabetes Mellitus. 
2. Known case of CAD. 
3. Signs of left ventricular failure. 
4. Patients with peripheral vascular disease as evidenced 
by absent peripheral pulses. 
5. Patients without microvascular complication. 
(i) Retinopathy excluded by fundus examination. 
(ii) Albimunuria by dispstic method. 
(iii) Autonomic neuropathy. 
6. Uncontrolled Systemic hypertension. 
7. Age less than 30 years and more than 65 years. 
8. Other absolute contraindications for exercise stress test. 
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STUDY POPULATION 
 Of the 205 patients enrolled for the study who attended out 
patient department of Government Kilpauk Medical College Hospital, 
40 Patients of type 2 DM were selected for Treadmill test. Rest of 
the patients excluded as per exclusion criteria. 20 non diabetic 
patients also selected as control. Tread mill test was performed for 
these 60 patients using standard bruce protocol.  
STUDY DESIGN 
Case – Control Study 
LABORATORY METHODS 
 Fasting plasma glucose was measured overnight fasting 
sample and 2 hour post prandial glucose measured from the sample 
taken 2 hours after routine break fast by semi autoanalyser using 
glucose oxidase and pyruvate oxidase method. 
 For lipid profile (Serum total cholesterol, HDL, TGL) after 12 
hours of overnight fasting and were measured by ERBA KIT semi 
autoanalyser using enzymatic method. Serum LDL was calculated 
using 
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FRIEDWALD’S  FORMULA 
LDL = TC – HDL – TGL / 5 if total cholesterol is less than 100 
mg / dl. 
 From the patient height and weight BMI was calculated by 
using the formula: 
 BMI = Weight in Kg / (Height in meters)2 
TREAD MILL TEST 
Techniques 
1. The standard Bruce protocol was used since large diagnostic 
and prognostic data has been published using this protocol. 
The bruce multistage maximal treadmill protocol has 3 
minutes periods to allow achievement of steady state before 
work load is increased. 
2. Patients were instructed not to eat or drink caffeinated 
beverages for 3 hours before testing and to wear comfortable 
shoes and loose fitting cloths. 
3. Unusuals physical exertion was avoided before testing. 
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4. Patients were advised about the risk and benefits of the 
procedure. 
5. A written informed consent form was obtained. 
6. Adequate skin preparation was done to obtain high quality 
recordings. 
7. The areas of electrode application are rubbed with an alcohol 
pad to remove oil & rubbed with free sand paper and a rough 
material to reduce skin resistance to 5000 ohms. 
8. Cables connecting the electrodes and recorders were light 
flexible and properly shielded. 
9. Room temperature was adjusted between 64 and 72°F (18 & 
22°C) and humidity less than 60%.  
10. Tread mill walking was demonstrated to the patients. 
11. The heart rate, blood Pressure and ECG were recorded at the 
end of each stage of exercise. Immediately before & 
immediately after stopping exercise, at the onset of an 
ischemic response and for each minute for at least 5-10 
minutes in the recovery phase. 
 44
12. A minimum of three leads were displayed continuously on the 
monitor during the test. 
13. Patients were at the sitting position immediately after the 
exertion. 
14. The supine position was avoided because it increases end 
diastolic volume and has the potential to augment ST 
segment changes. 
TMT RESULTS INTERPRETATION  
Normal response 
 In normal persons, PR, QRS and QT intervals shorten as the 
heart rate increases. P amplitude increases and PR segment 
becomes progressively more downsloping in the inferior leads. J 
point or junctional depression is the normal finding during exercise. 
Abnormal response 
 The development of 0.1 mV (1 mm) or greater of J point 
depression measured form the PQ junction with a relatively flat ST 
segment slope depressed 0.1 mV or more 80 m.sec. after the J 
point (ST 80) in 3 consecutive beats with a stable baseline is 
considered to be  an abnormal response. When the ST 80 
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measurement is difficult to determine at rapid heart rate (>130 
beats/min), ST 60 measurement is used. 
In our study 
1. ST segment depression of ≥ 1mm during exercise and 
early recovery period was considered to be TMT positive 
for inducible ischemia. 
2. Development of classical angina during the test is 
considered to be strongly positive response. 
3. Patients who have not completed stage III and failed to 
achieve 85% of target hear rate, the TMT results are 
declared inconclusive. 
Workload 
 Workdone during the exercise stress test is expressed in MET 
(Metabolic equivalents). 1 MET = 3.5 ml/O2/min/Kg of body weight. 
Exercise time 
 Exercise time is calculated in minutes. Each stage is consisted 
of 3 minutes 
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Hypertensive Response 
 Hypertensive response during treadmill was considered when 
systolic BP more than 214 mmHg. These types of patients are more 
prone to develop hypertension in the future. 
The TMT was terminated if the patient developed any of the 
following features. 
1. Drop in systolic blood pressure despite an increase in 
workload. 
2. When accompanied by other evidence of ischemia. 
3. Moderate to severe angina (grade 3/4). 
4. Increasing nervous system symptoms (e.g., ataxia, 
dizziness or near syncope). 
5. Signs of poor perfusion (cyanosis or pallor). 
6. Technical difficulties in monitoring ECG or systolic blood 
pressure. 
7. Subject’s desire to stop. 
8. Sustained ventricular tachycardia. 
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9. ST elevation (≥1.0mm) in non infarct leads without 
diagnostic Q waves (other than V1 or a VL). 
10. Fatigue, shortness of breath, wheezing, leg cramps, or 
claudication. 
11. Development of bundle branch block or intra ventricular 
conduction delay that cannot be distinguished from 
ventricular tachycardia. 
12. Hypertensive response. 
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RESULTS AND OBSERVATIONS 
 Statistical analysis was carried out for diabetic patients 
(Cases) and non diabetic (Controls) after categorizing each variable. 
Age, Duration of Diabetics, Sex, BMI, WHR, Systemic hypertension, 
smoking, dyslipidemia were analysed among diabetic with TMT 
positive and Diabetic with TMT negative and non diabetic controls. 
The significance of difference in means between two groups was 
calculated using student ‘t’ test and significance of difference in 
proportion using chi-square test. FISHER EXACT TEST was used 
when any one of the expected variable was less than 5 in chi-square 
test. 
 Statistical significance is taken when P < 0.05. Statistical 
analysis was carried out using standard formula. Microsoft Excel 
2007 version and Number crunch statistical software (NCSS) were 
used for data entry and analysis. 
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 40 Diabetic patients, ten of them newly detected Diabetic 
patients, rest 30 patients of known diabetes of various duration and 
20 non-diabetic controls underwent Tread mill test. Tread mill test 
was done by standard Bruce protocol.  Among 40 diabetic patients 2 
patients are excluded from the study because their Treadmill test 
results are inconclusive. 
 In our study cases and controls are analysed for age, BMI, 
WHR, dyslipidemia, Hypertension and smoking. 
Table 1: STUDY GROUP 
Study Group Number of Patients 
Case 38 
Control 20 
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Table 2: PATIENTS CHARACTERISTICS 
Case Number 38 Control Number 20 
95% of C.I. 95% of C.I. 
S.No. 
Variable Mean LCL 
of 
Mean 
UCL 
of 
Mean 
Mean LCL 
of 
Mean 
UCL 
of 
Mean 
P 
Value 
1 Age 48.39 45.70 51.07 46.4 43.10 49.69 0.35 
2 BMI 25.26 24.22 26.29 23.71 22.38 25.03 0.06 
3 WHR 0.80 0.77 0.83 0.76 0.74 0.79 0.07 
 
Observation: There is no statistically significant difference noted in 
Age, BMI, WHR (P value is more than 0.05).  However BMI and 
WHR are higher in Diabetic population (cases) than controls. 
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Table 3: LIPID PROFILE 
Case                 N = 38 Control             N = 20 
95% of C.I. 95% of C.I. S.No. 
Variable Mean 
LCL of 
Mean 
UCL 
of 
Mean 
Mean 
LCL of 
Mean 
UCL 
of 
Mean 
P 
Value 
1 TC 200.81 189.28 212.34 205.65 189.40 221.89 0.61 
2 TGL 151.36 129.52 173.21 141.65 127.64 155.65 0.53 
3 HDL 28.63 27.40 29.86 35.85 33.87 37.82 0.00 
4 LDL 141.23 129.67 152.79 136.45 121.71 151.18 0.61 
 
 In Lipid profile, there is statistically significant difference is 
noted in HDL with ‘P’ value of 0.0000. Total cholesterol (T.C.), 
Triglycerides (TGL) and low density Lipo proteins (LDL) do not show 
any statistically significant difference. 
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Table 4: PATIENTS CHARACTERISTICS 
 
Cases 
Number 
38 
Percentage 
Control 
Number 
20 
Percentage 
P 
Value 
Hyper 
Tension 
19 50 7 35 0.27 
Smoking 10 26 6 30 0.08 
Family 
History 
of 
Diabetes 
23 61 6 30 0.02 
Family 
History 
of IHD 
6 10 1 5 0.40 
 
Observation: There is no statistically significant difference noted 
regarding hypertension, smoking, family history of IHD between 
cases and controls. 
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Table 5: TMT PARAMETERS 
Case Number Control Number 
95% of C.I. 95% of C.I. 
S.No. 
Variable Mean LCL 
of 
Mean 
UCL 
of 
Mean 
Mean LCL 
of 
Mean 
UCL 
of 
Mean 
P 
Value 
1 
Exercise 
Time 
7.39 6.82 7.97 8.82 8.12 9.52 0.0031 
2 
Work load 
in mets 
9.13 8.46 9.79 10.88 9.95 11.81 0.0025 
3 
Percentage 
of  
Predicted 
Maximum 
Hear rate 
91.18 88.27 94.09 95.15 93.23 97.06 0.06 
 
 TMT parameters like exercise duration in minutes, work load 
in mets and percentage of Target heart rate achieved are analysed 
between cases and controls. 
Observation: There is a statistically significant difference noted 
between cases and controls in exercise duration and work load with 
a P value 0.0031 and 0.0025 respectively. 
 Diabetic patients are divided in to two groups TMT positive 
group and TMT negative group.  These two groups are analysed.  
Among 38 cases 10 cases are TMT positive and 28 cases are TMT 
negative. 
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Table 6: PREVALENCE OF SILENT MYOCARDIAL ISCHEMIA IN 
CASES AND CONTROL 
Total number of Patients 
Number of TMT 
positive case 
Percentage 
Diabetic cases Number 38 10 26 
Control Number 20 1 5 
 
Observation: 26% among diabetic patients are positive for silent 
myocardial ischemia against 5% in control. 
Table 7: PREVALENCE OF SILENT MYOCARDIAL ISCHEMIA IN 
MALES AND FEMALES 
 
Total Number 
of Patients 
TMT Positive Percentage 
Male 21 6 29 
Female 17 4 24 
 
Observation: 29% of males and 24% of females are TMT positive. 
The ‘P’ value is 1.00 that is prevalence is almost equal in both 
sexes. 
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Table 8: PREVALENCE OF SILENT MYOCARDIAL ISCHEMIA 
WITH RESPECT TO DURATION OF DIABETES 
Duration of 
Diabetics 
No. of 
Patients 
TMT positive Percentage 
Newly Detected 10 1 10 
7 months to 5 years 9 2 22 
6 to 10 years 10 3 30 
More than 10 years 9 4 44 
 
Observation: Prevalence in newly detected Type 2 Diabetes is 
10%.  As the duration increase the prevalence also increase from 
10% in newly detected to 22% of type 2 diabetic patients with 7 
months to 5 years duration, 30% in patients with 6-10 years 
duration and 44% in patients with more than 10 years duration. 
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Table 9: PATIENT CHARACTERISTICS 
TMT Positive 
Number 10 
TMT Negative 
Number 28 
95% of C.I. 95% of C.I. 
S.No. 
Variable Mean LCL 
of 
Mean 
UCL 
of 
Mean 
Mean LCL 
of 
Mean 
UCL 
of 
Mean 
P 
Value 
1 Age 52.4 46.97 57.82 46.96 43.85 50.07 0.07 
2 BMI 26.22 24.30 28.13 24.92 23.65 26.18 0.26 
3 WHR 0.80 0.74 0.86 0.80 0.77 0.84 0.94 
4 
Age of 
onset of 
diabetes 
40.8 33.38 48.21 41.96 38.36 45.56 0.74 
5 
Duration 
of 
Diabetes 
10.5 3.29 17.7 5 3.03 6.98 0.031 
 
Observation: There is a statistically significant difference exists 
between TMT positive group and TMT negative group regarding 
duration of diabetes.  Age, BMI, WHR, age of onset of diabetes does 
not show any difference. 
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Table 10: LIPID PROFILE 
TMT Positive 
Number 10 
TMT Negative 
Number 28 
95% of C.I. 95% of C.I. 
S.No. 
Variable Mean 
LCL of 
Mean 
UCL 
of 
Mean 
Mean 
LCL of 
Mean 
UCL 
of 
Mean 
P 
Value 
1 TC 200 174.57 227.02 200.82 187.17 214.46 0.99 
2 TGL 169.3 113.25 225.34 144.96 120.92 169.00 0.39 
3 HDL 26.9 24.11 29.68 29.25 27.87 30.42 0.08 
4 LDL 137.7 111.77 163.62 142.5 128.79 156.21 0.71 
  
Observation: There is no statistically significant difference in Lipid 
profile between TMT positive and TMT negative group. 
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Table 11: ANALYSIS OF RISK FACTORS-HYPERTENSION, 
SMOKING, FAMILY HISTORY OF IHD BETWEEN TMT 
POSITIVE AND TMT NEGATIVE GROUP 
Risk 
Factors 
TMT 
Positive 
Number 
10 
Percentage 
TMT 
Negative 
Number 
28 
Percentage 
P 
value 
Hyper 
tension 
8 80 11 39 0.02 
Smoking 5 50 15 18 0.04 
Family 
History 
of IHD 
3 30 3 11 0.31 
 
Observation: There is statistically significant difference noted in 
Hypertension and smoking with a P value of 0.027 and 0.047 
respectively between TMT positive and TMT negative groups. 
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Table 12: TMT PARAMETERS 
TMT Positive 
Number 10 
TMT Negative 
Number 28 
95% of C.I. 95% of C.I. 
S.No. 
Variable Mean 
LCL 
of 
Mean 
UCL 
of 
Mean 
Mean 
LCL 
of 
Mean 
UCL 
of 
Mean 
P 
Value 
1 
Exercise 
time 
6.40 5.45 7.85 7.75 7.06 8.44 0.03 
2 
Work 
load in 
mets 
8.31 7.32 9.29 9.42 8.58 10.25 0.13 
3 
% 
Predicted 
Maximum 
H.R. 
94.8 89.54 100.05 89.89 86.36 93.42 0.13 
 
Observation: There is a statistical significant difference noted in 
exercise time with a P value of 0.035 between TMT positive and TMT 
negative groups. 
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DISCUSSION 
 In our study the prevalence of silent myocardial ischemia is 
26% in Diabetics and 5% in controls. This shows silent myocardial 
ischemia is more common in Diabetics than non-diabetics (26% Vs 
5%). In various international studies the prevalence of silent 
myocardial ischemia varies between 10-77%. The DIAD study67 
which is the first large prospective study in asymptomatic patients 
with diabetes revealed a prevalence of silent myocardial ischemia of 
22%. In the study done by Koistinen et al,43 the prevalence of SMI 
is 29%. In another study conducted at Department of Medicine, 
cardiology division, New York Medical College, New York, USA,68 the 
Prevalence of SMI in Type 2 diabetics is 29%.  Our study result 
exactly matches with these studies. 
 In one study conducted in Department of Cardiology, central 
railway head quarter hospital Byculla, Bombay, the prevalence of 
SMI is 38%. In another study done at Department of cardiology, All 
India Institute of Medical Science New Delhi,69 the prevalence of 
SMI is 50% by Treadmill test and 35% on ambulatory 
electrocardiography. 
 In our study the prevalence of SMI in newly detected Type 2 
Diabetes is 10%. As the duration increases, the prevalence also 
increases from 10% in newly detected to 22% in patients with  
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7 months to 5 years duration, 30% in patients of 6-10 years 
duration and 44% in patients with more than 10 years duration. 
Many studies have demonstrated the impaired glucose tolerance 
itself is a risk factor for CAD.  SMI is present even in the stage of 
impaired glucose tolerance. 
 In one study done at Department of medicine, cardiology 
Division, New York Medical College, Val Halla, New York70 and 
another study by Jackson et al,34 have demonstrated SMI is present 
at the stage of impaired glucose tolerance itself and the prevalence 
increases with duration and the level of glycemic control. 
 In our study the prevalence of Hypertension among diabetic is 
50%. The prevalence of Hypertension in TMT positive is 80% and 
TMT negative group is 39% with a ‘P’ value 0.027. Kannel WB71 and 
Stamler J72 have demonstrated that Hypertension increases the risk 
of CAD by two fold.  In our study also, Hypertension has increased 
two fold risk. 
Smoking is at least as prevalent among diabetic people as in 
general population and CAD already more common in Diabetic is 
even more prevalent in those who smoke.66  In our study 26% of 
Diabetic and 30% of non diabetic are smokers, ie. both smoke 
equally.  But in TMT positive group, prevalence of smoking is 50% 
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and in TMT negative group is 18% with a P value of 0.047.  This 
shows that smoking increases the risk more than two fold. 
 Type 2 diabetes show the characteristic Lipid Profile of normal 
or only slightly raised cholesterol, with low HDL cholesterol and 
mildly elevated triglyceride concentrations.73,74,75  In our study also 
total cholesterol is almost equal in both cases and controls. 
Triglyceride and low density lipo protein is mildly raised in Diabetic 
than controls but regarding HDL cholesterol, there is a significant 
difference between diabetic and control with a P value of 0.00.  
However there is no difference is noted between TMT positive and 
TMT negative group except for Triglycerides which is mildly 
increased in TMT positive (Mean: 169.3) than TMT negative group 
(Mean 144.96). 
 In our study regarding obesity, BMI and WHR are higher in 
Diabetics than control. (BMI Mean 25.26 Vs 23.71, WHR Mean 0.80 
Vs 0.76).  However there is no statistically significant difference.  
Similarly there is no difference in WHR between TMT positive and 
TMT negative group.  BMI is higher in TMT positive than TMT 
negative group (Mean TMT positive 26.22, TMT negative 24.92).  
However there is no statistically significant difference. 
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CONCLUSION 
1. The prevalence of silent myocardial ischemia is higher in 
diabetic when compared to non-diabetic. Silent myocardial 
ischemia is present in diabetic patients even at the time of 
detection itself. 
2. As the duration of diabetes increases, the prevalence of silent 
myocardial ischemia also increases. 
3. Though Hypertension, smoking, dyslipidemia are independent 
risk factor for CAD, The association of these risk factors in 
diabetes further amplifies the risk of CAD in diabetic patients. 
4. Detection of silent myocardial ischemia-a silent disease 
marker which is more prevalent in diabetic can lead to the 
prevention of CAD which is more common, extensive and fatal 
in diabetes. 
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